| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Vivos Therapeutics, Inc.
13D
VVOS · 92859E207
|
19.9% |
7/15/2026
Event 6/30/2026
|
||||
| V-CO Investors LLC | 3.7% | |||||
| V-Co Investors 2 LLC | 5.9% | |||||
| V-Co Investors 3 LLC | 9.7% | |||||
| V-Co Investors 4 LLC | 0.6% | |||||
| SP Manager LLC | 19.9% | |||||
| Michael C. Skaff | 19.9% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.